Industry: Pharmaceuticals, Biotechnology
Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus, specializes in the discovery and development of innovative therapies for the treatment of immune-mediated disorders. The company’s therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders, graft rejection, cancer and chronic viral diseases. TTI is primarily involved in the development of protein therapeutics, such as monoclonal antibodies, secreted proteins and peptides. The company’s business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical ( www.trilliumtherapeutics.com )
Trillium Therapeutics Inc.
96 Skyway Ave.
Toronto, Ontario M9W 4Y9
Canada
Tel: (416) 595-0627
Fax: (416) 595-5835